PPT-Effects of antiplatelet therapy after stroke due to

intracerebral haemorrhage ICH extended followup of the RE start or ST op A ntithrombotics R andomised T rial RESTART RESTART Collaboration wwwRESTARTtrialorg Intracerebral haemorrhage ICH is associated with an increased risk of arterial ischaemic events pooled analysis of 4 populationbased cohorts. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. National Stroke Association. ADVOCATE. – Influence public policy and legislation on stroke survivor issues.. EDUCATE. – Spread the word about stroke awareness.. PARTICIPATE. – Get involved and make a difference in the world of stroke.. National Stroke Association. ADVOCATE. – Influence public policy and legislation on stroke survivor issues.. EDUCATE. – Spread the word about stroke awareness.. PARTICIPATE. – Get involved and make a difference in the world of stroke.. Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . Assist.Lect. . . Shaymaa. . Hasan. Abbas. DESIRED TREATMENT OUTCOMES. The short-term goals of treatment for acute ischemic stroke include reducing secondary brain damage by re-establishing and maintaining adequate perfusion to marginally ischemic areas of the brain and to protect these areas from the effects of ischemia (i.e., . David . Maung. , Tristan . Reichardt. , Dan . Bibyk. , Juan Roman. Department of Computer Science and Engineering. The Ohio State University. The Problem. Constraint-Induced . therapy is unavailable to most patients due to its cost, travel/scheduling demands, and . OHHI Cardiology Group. Antiplatelet and Anticoagulation Therapy – What You Need to Know. Objectives. Utilize current practice guidelines for the management of antiplatelet therapy in CAD patients..